Substance P as a Novel Anti-obesity Target

Gastroenterology

Volumn 134, Issue 3, 2008, Pages

  Karagiannides, Iordanes ^a   Torres, Daniel ^a   Tseng, Yu Hua ^b   Bowe, Collin ^a   Carvalho, Eugenia ^a   Espinoza, Daniel ^a   Pothoulakis, Charalabos ^a,c   Kokkotou, Efi ^a,c  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIOBESITY AGENT; CJ 012255; INSULIN; LEPTIN; NEUROKININ 1 RECEPTOR; NEUROKININ 1 RECEPTOR ANTAGONIST; SUBSTANCE P; SUBSTANCE P ANTAGONIST; TACHYKININ; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APPETITE; ARTICLE; BODY WEIGHT; BRAIN REGION; CONTROLLED STUDY; DOSE RESPONSE; DRUG MECHANISM; DRUG MEGADOSE; DRUG TARGETING; ENERGY BALANCE; FEEDING BEHAVIOR; HYPOTHALAMUS; INSULIN SENSITIVITY; LOW DRUG DOSE; MALE; MOUSE; MOUSE STRAIN; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN LOCALIZATION; WEIGHT REDUCTION;

EID: 39749152943     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.gastro.2007.12.032     Document Type: Article

References (48)

1. A.H. Mokdad J.S. Marks D.F. Stroup Actual causes of death in the United States, 2000 JAMA 291 2004 1238 1245
2. P.G. Kopelman Obesity as a medical problem Nature 404 2000 635 643
3. J.M. Friedman Obesity in the new millennium Nature 404 2000 632 634
4. M.K. Badman J.S. Flier The gut and energy balance: visceral allies in the obesity wars Science 307 2005 1909 1914
5. P. Abelson D. Kennedy The obesity epidemic Science 304 2004 1413
6. C.L. Ogden M.D. Carroll L.R. Curtin Prevalence of overweight and obesity in the United States, 1999–2004 JAMA 295 2006 1549 1555
7. M.A. Lazar How obesity causes diabetes: not a tall tale Science 307 2005 373 375
8. T. Gura Obesity drug pipeline not so fat Science 299 2003 849 852
9. G.A. Bray L.A. Tartaglia Medicinal strategies in the treatment of obesity Nature 404 2000 672 677
10. M.M. Chang S.E. Leeman Isolation of a sialogogic peptide from bovine hypothalamic tissue and its characterization as substance P J Biol Chem 245 1970 4784 4790
11. P. Holzer Local effector functions of capsaicin-sensitive sensory nerve endings: involvement of tachykinins, calcitonin gene-related peptide and other neuropeptides Neuroscience 24 1988 739 768
12. J.P. Lai S.D. Douglas W.Z. Ho Human lymphocytes express substance P and its receptor J Neuroimmunol 86 1998 80 86
13. D.W. Pascual K.L. Bost Substance P production by P388D1 macrophages: a possible autocrine function for this neuropeptide Immunology 71 1990 52 56
14. C. Severini G. Improta G. Falconieri-Erspamer The tachykinin peptide family Pharmacol Rev 54 2002 285 322
15. C. De Felipe J.F. Herrero J.A. O’Brien Altered nociception, analgesia and aggression in mice lacking the receptor for substance P Nature 392 1998 394 397
16. Y.Q. Cao P.W. Mantyh E.J. Carlson Primary afferent tachykinins are required to experience moderate to intense pain Nature 392 1998 390 394
17. P. Holzer U. Holzer-Petsche Tachykinins in the gut Part I. Expression, release and motor function Pharmacol Ther 73 1997 173 217
18. C. Pothoulakis I. Castagliuolo J.T. LaMont CP-96,345, a substance P antagonist, inhibits rat intestinal responses to Clostridium difficile toxin A but not cholera toxin Proc Natl Acad Sci U S A 91 1994 947 951
19. M. Riegler I. Castagliuolo P.T. So Effects of substance P on human colonic mucosa in vitro Am J Physiol 276 1999 G1473 G1483
20. I. Castagliuolo L. Valenick J. Liu Epidermal growth factor receptor transactivation mediates substance P-induced mitogenic responses in U-373 MG cells J Biol Chem 275 2000 26545 26550
21. C. Pothoulakis I. Castagliuolo S.E. Leeman Substance P receptor expression in intestinal epithelium in Clostridium difficile toxin A enteritis in rats Am J Physiol 275 1998 G68 G75
22. K. Tsuchida R. Shigemoto Y. Yokota Tissue distribution and quantitation of the mRNAs for three rat tachykinin receptors Eur J Biochem 193 1990 751 757
23. A. Stewart-Lee G. Burnstock Actions of tachykinins on the rabbit mesenteric artery: substance P and [Glp6,L-Pro9]SP6-11 are potent agonists for endothelial neurokinin-1 receptors Br J Pharmacol 97 1989 1218 1224
24. M.K. Schafer D. Nohr J.E. Krause Inflammation-induced up-regulation of NK1 receptor mRNA in dorsal horn neurones Neuroreport 4 1993 1007 1010
25. T.M. O’Connor J. O’Connell D.I. O’Brien The role of substance P in inflammatory disease J Cell Physiol 201 2004 167 180
26. L. Quartara C.A. Maggi The tachykinin NK1 receptor Part I: ligands and mechanisms of cellular activation Neuropeptides 31 1997 537 563
27. L. Quartara C.A. Maggi The tachykinin NK1 receptor Part II: Distribution and pathophysiological roles Neuropeptides 32 1998 1 49
28. R.A. Duffy Potential therapeutic targets for neurokinin-1 receptor antagonists Expert Opin Emerg Drugs 9 2004 9 21
29. J.B. Furness TAK-637 Takeda Curr Opin Investig Drugs 2 2001 1437 1440
30. R.M. Snider J.W. Constantine J.A. Lowe III A potent nonpeptide antagonist of the substance P (NK1) receptor Science 251 1991 435 437
31. A.F. Stucchi K.O. Shebani S.E. Leeman A neurokinin 1 receptor antagonist reduces an ongoing ileal pouch inflammation and the response to a subsequent inflammatory stimulus Am J Physiol Gastrointest Liver Physiol 285 2003 G1259 G1267
32. K.L. Reed A.B. Fruin A.C. Gower A neurokinin 1 receptor antagonist decreases postoperative peritoneal adhesion formation and increases peritoneal fibrinolytic activity Proc Natl Acad Sci U S A 101 2004 9115 9120
33. I. Karagiannides E. Kokkotou M. Tansky Induction of colitis causes inflammatory responses in fat depots: evidence for substance P pathways in human mesenteric preadipocytes Proc Natl Acad Sci U S A 103 2006 5207 5212
34. H. Xu G.T. Barnes Q. Yang Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance J Clin Invest 112 2003 1821 1830
35. P.W. Mantyh S.P. Hunt J.E. Maggio Substance P receptors: localization by light microscopic autoradiography in rat brain using [3H]SP as the radioligand Brain Res 307 1984 147 165
36. M. Brown W. Vale Effects of neurotensin and substance P on plasma insulin, glucagon and glucose levels Endocrinology 98 1976 819 822
37. G.S. Barsh I.S. Farooqi S. O’Rahilly Genetics of body-weight regulation Nature 404 2000 644 651
38. R.U. Hasenohrl R.K. Schwarting P. Gerhardt Comparison of neurokinin substance P with morphine in effects on food-reinforced operant behavior and feeding Physiol Behav 55 1994 541 546
39. B. Dib Food and water intake suppression by intracerebroventricular administration of substance P in food- and water-deprived rats Brain Res 830 1999 38 42
40. S.A. Tucci J.C. Halford J.A. Harrold Therapeutic potential of targeting the endocannabinoids: implications for the treatment of obesity, metabolic syndrome, drug abuse and smoking cessation Curr Med Chem 13 2006 2669 2680
41. B.M. Chronwall Anatomy and physiology of the neuroendocrine arcuate nucleus Peptides 6 Suppl 2 1985 1 11
42. E. Challet E. Naylor J.M. Metzger An NK1 receptor antagonist affects the circadian regulation of locomotor activity in golden hamsters Brain Res 800 1998 32 39
43. K. Treptow R. Morgenstern P. Oehme The essential sequence of substance P for locomotion Pharmazie 41 1986 727 729
44. K. Treptow P. Oehme E. Gabler Modulation of locomotor activity by substance P in rats Regul Pept 5 1983 343 351
45. R.L. Bradley J.P. Mansfield E. Maratos-Flier Neuropeptides, including neuropeptide Y and melanocortins, mediate lipolysis in murine adipocytes Obes Res 13 2005 653 661
46. C.G. Nicholl J.M. Polak S.R. Bloom The hormonal regulation of food intake, digestion, and absorption Annu Rev Nutr 5 1985 213 239
47. J. Herrstedt H.B. Muss D.G. Warr Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and emesis over multiple cycles of moderately emetogenic chemotherapy Cancer 104 2005 1548 1555
48. E.K. Kim I. Miller L.E. Landree Expression of FAS within hypothalamic neurons: a model for decreased food intake after C75 treatment Am J Physiol Endocrinol Metab 283 2002 E867 E879